KalVista Pharmaceuticals (KALV) Capital Expenditures Growth (3y) (2019 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 46.88% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.97% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 16.27% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -45.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -45.74% |
| Apr 30, 2025 | 58.43% |
| Oct 31, 2024 | -43.27% |
| Jul 31, 2024 | -39.36% |
| Apr 30, 2024 | -112.80% |
| Jan 31, 2024 | 173.37% |
| Oct 31, 2023 | -46.42% |
| Jul 31, 2023 | -35.15% |
| Apr 30, 2023 | 105.08% |
| Oct 31, 2022 | 18.98% |
| Jul 31, 2022 | 110.95% |
| Apr 30, 2022 | -32.12% |
| Jan 31, 2022 | 116.16% |
| Oct 31, 2021 | 17.22% |
| Jul 31, 2021 | -20.21% |
| Apr 30, 2021 | -68.78% |
| Jan 31, 2021 | -57.47% |
| Oct 31, 2020 | -36.59% |
| Jul 31, 2020 | -41.52% |
| Apr 30, 2020 | 4.55% |
| Oct 31, 2019 | 85.02% |
| Jul 31, 2019 | 31.60% |